Adverse reactions of montelukast in the treatment of pediatric asthma: an integrative literature review
DOI:
https://doi.org/10.22421/1517-7130/es.2022v23.e869Keywords:
Asthma, Pediatric, MontelukastAbstract
We sought to analyze the adverse reactions of montelukast when prescribed for the treatment of pediatric asthma. Integrative literature review using the databases: U.S. National Library of Medicine (PubMed), Virtual Health Library (BVS), SCOPUS and Business Source Complete (EBSCO), using the descriptors: "asthma", "pediatric", "montelukast" and "adverse effects", joined by the Boolean “ AND''. Articles were included in their entirety, published in the last 5 years, written in Portuguese, English or Spanish, researched in humans and related to our objective. Those that met our exclusion criteria were excluded. Fifty-three articles were identified, of which 11 comprised the final sample of this review. Exposure to montelukast was associated with a 2-fold greater chance of neuropsychiatric reactions in one of the analyzed articles, but the studies have not yet provided a common pathophysiological explanation. Reactions neuropsychiatric disorders were the most prevalent, representing more than 90% of the sample.
References
Acoglu EA, Yazilitas F, Gurkan A, Sari E, Senel S, Akcaboy M. Eosinophilic Granulomatosis with Polyangiitis in a 4-Year-Old Child: Is Montelukast and/or Clarithromycin a Trigger? Archives of Iranian Medicine. 2019;22(3):161-163. Disponível em http://www.aimjournal.ir/Article/aim-3208.
Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase. Drug Safety. 2015; 39(1):69–78. Disponível em: https://doi.org/ 10.1007/s40264-015-0360-2.
Ali MM, O’Brien CE, Cleves MA, Martin BC. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study. Pharmacoepidemiology and Drug Safety. 2015; 24(4):435–45. Disponível em: https://doi.org/ 10.1002/pds.3758.
Arnold Donald H, Bowman N, Reiss TF, Hartert TV, Akers WS, Seger DL. Adverse events associated with weight-based, high-dose montelukast exposures in children, Clinical Toxicology, 2019 [acesso em 08 ago 2020]; 58(2):145–6. Disponível em: https://doi.org/10.1080/15563650.2019.1609686
Baan EJ, Smet VA, Hoeve CE, Pacurariu AC, Sturkenboom MCJM, Jongste JC, Janssens HM, Verhamme KMC. Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports. Drug Safety, 2020 [Acesso em 08 ago 2020]; 43:7-16. Disponível em: https://doi.org/10.1007/s40264-019-00870-x.
Benard B, Bastien V, Vinet B. et al. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur Respir J. 2017 [acesso em 16 ago 2020]; 50 (5). Disponível em: https://doi.org/10.1183/13993003.00148-2017.
Carnovale C., Gentili M, Antoniazzi S, Radice S, Clementi, E. Montelukast-induced metamorphopsia in a pediatric patient. A case report and a pharmacovigilance database analysis. Annals of Allergy, Asthma and Imunology. 2016 [Acesso em 04 ago 2020]. 116(4):370–1. Disponível em: https://doi.org/10.1016/j.anai.2016.01.013.
Chong Neto HJ, Solé D, Camargos P, Rosário NA, Asrinho EC, Chong-Silva DC et al.(Orgs.). Diretrizes da Associação Brasileira de Alergia e Imunologia e Sociedade Brasileira de Pediatria para Sibilância e Asma no Pré-Escolar. Arq Asma Alerg Imunol. 2018 [acesso em 27 jul 2020]; 2(2):163-208. Disponível em: http://dx.doi.org/10.5935/2526-5393.20180020.
Erdem SB, Karaman SK, Nacaroglu HT, Karkiner CSU, Yazici S, Can D. Seizures as a rare but serious adverse effect of leukotriene receptor. Annals Allergy Asthma Immunol. 2016 [acesso em 04 ago 2020]; 117(1):99–101. Disponível em: https://doi.org/10.1016/j.anai.2016.01.013.
Esty B, Permaul P, Deloreto K, Baxi SN, Phipatanakul W. Asthma and Allergies in the School Environment. Clinical Reviews in Allergy & Immunology. 2019 [acesso em 08 ago 2020]; 57(3):415-426. Disponível em: https://doi.org/10.1007/s12016-019-08735-y.
FDA. Drugs.[acesso em 28 Jul 2020]. Disponível em: https://www.accessadata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s52_021409s028lbl.pdf
FDA. Drug safety and availability. [acesso em 10 ago 2020]. Disponível em: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug.
GINA – Global Initiative for Asthma – Global Strategy for Asthma Management and Prevention. 2020 [acesso em 10 ago 2020]. Disponível em: www.ginasthma.org.
Glockler-Lauf SD, Finkelstein Y, Zhu J, Feldman LY, TT. Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case–Control Study. The Journal of Pediatrics. 2019 [Acesso em 26 Jul 2020]; 146(4): 371-2. Disponível em: https://pediatrics.aappublications.org/content/146/Supplement_4/S371.2
Haarmann MG, Van Hunsel F, De Vries TW. Adverse drug reactions of montelukast in children and adults. Pharmacology Research & Perspectives. 2017 [acesso em 14 ago 2020]; 5(5). Disponível em: https://doi.org/10.1002/prp2.341.
Kliegman RM. Nelson textbook of pediatrics. Philadelphia: Elsevier; 2016.
Lin Y-C, Huang M-Y, Lee M-S, Hsieh C-C, Kuo H-F, Kuo C-H, et al. Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages. Journal of Microbiology, Immunology and Infection. 2018;51(1):18–26. Disponível em: https://doi.org/10.1016/j.jmii.2016.04.005.
Lopez FA, Campos Junior, DB. Tratado de pediatria. Barueri: Manole; 2017.
Lu CY, Zhang F, Lakoma MD, Butler MG, Fung V, Larkin EK, Kharbanda EO, Vollmer WM, Lieu T, Soumerai SB, Wu AC. Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. Clinical Therapeutics. 2015 [acesso em 04 ago 2020]; 37(6):1280–91. Disponível em: http://dx.doi.org/10.1016/j.clinthera.2015.03.027 0149-2918/.
Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a Incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm, 2008; 17(4): 758-64. Disponível em: https://doi.org/10.1590/S0104-07072008000400018
Pizzichini MMM, Carvalho-Pinto RM de, Cançado JED, Rubin, Cerci Neto A, Cardoso AP, et al. Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia - 2020. Jornal Brasileiro de Pneumologia [Internet]. 2020;46(1). Disponível em: https://www.scielo.br/scielo.php?pid=S180637132020000100400&script=sci_arttext&tlng=pt#B12
Rang HP, Ritter JM, Flower RJ, Graeme Henderson, Gorio A, Maria A, et al. Rang & Dale Farmacologia. Milano Edra; 2016.
Souza MT, Silva MD, Carvalho R. Revisão Integrativa: o que é e como fazer. Einstein. 2010; 8(1):102-6. Disponível em: https://doi.org/10.1590/S1679-45082010RW1134
Vinay Kumar, Abbas AK, Aster JC, Wojciech Biernat, Włodzimierz Olszewski, Perkins JA, et al. Robbins patologia. Wrocław: Edra Urban & Partner, Copyright; 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Espaço para a Saúde
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors grant the journal the copyright, with the work simultaneously licensed with Creative Commons CC BY, which allows the sharing of work with recognition of authorship and initial publication in this journal.
- Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g., to publish in an institutional repository or as a book chapter), with authorship recognition and initial publication in this journal.
- Authors are permitted and encouraged to publish and distribute their work online (e.g., in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and the citation of the published work (See The Effect of Free Access).
